Jonathan I. Epstein

发表

Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.

J. Oesterling, P. Walsh, J. Epstein, 1987, The Journal of urology.

Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.

A W Partin, A. Partin, P. Walsh, 1993, The Urologic clinics of North America.

Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience

Alan W Partin, Bruce J Trock, H Ballentine Carter, 2011 .

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.

P. Walsh, J. Epstein, H. Carter, 2002, The Journal of urology.

The pathological interpretation and significance of prostate needle biopsy findings: implications and current controversies.

J. Epstein, S. Potter, Jonathan I. Epstein, 2001, The Journal of urology.

Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men.

D. Sundi, Oleksandr N. Kryvenko, Jonathan I. Epstein, 2014, The Journal of urology.

Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy.

J. Cadeddu, A. Partin, P. Walsh, 1997, Urology.

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.

D. Chan, P. Walsh, L. Sokoll, 1998, The Journal of urology.

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.

A. Partin, P. Landis, Zhaoyong Feng, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

J. Epstein, Misop Han, H. Carter, 2013, The Journal of urology.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

B. Trock, A. Partin, R. Veltri, 2012, The Journal of urology.

Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care.

A. Kibel, M. Roobol, M. Emberton, 2013, European urology.

Baseline prostate health index risk category and risk category changes during active surveillance predict grade reclassification.

B. Trock, K. Macura, M. Mamawala, 2023, Urologic oncology.

ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.

A. Partin, L. Sokoll, J. Epstein, 2011, Urology.

Biopsy criteria for determining appropriateness for active surveillance in the modern era.

B. Trock, J. Epstein, H. Carter, 2014, Urology.

Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes.

Katarzyna J Macura, Bruce J Trock, H Ballentine Carter, 2015, Urology.

Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance

Jonathan I. Epstein, Mufaddal Mamawala, L. Sokoll, 2017, Prostate Cancer and Prostatic Diseases.

Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group

J. Epstein, J. Tosoian, H. Carter, 2018, JAMA Oncology.

Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.

A W Partin, A. Partin, P. Walsh, 1993, The Journal of urology.

Diagnostic challenges of clonal heterogeneity in prostate cancer.

A. D. De Marzo, J. Epstein, H. Carter, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools.

P. Choyke, J. Epstein, J. Tosoian, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer.

P. Walsh, J. Epstein, H. Carter, 1997, The Journal of urology.

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

F. Marshall, A. Partin, P. Walsh, 1995, Urology.